<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medgen</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская генетика</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Genetics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-7998</issn><publisher><publisher-name>Publishing House «Genius Media» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25557/2073-7998.2018.09.37-44</article-id><article-id custom-type="elpub" pub-id-type="custom">medgen-583</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Частоты аллелей и генотипов, ассоциированных с чувствительностью к антикоагулянтам из группы антагонистов витамина К, в казахской популяции</article-title><trans-title-group xml:lang="en"><trans-title>Frequency of alleys and genotypes associated with sensitivity to anticoagulants from the group of vitamin K antagonists in the Kazakh population</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Святова</surname><given-names>Г. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Svyatova</surname><given-names>G. S.</given-names></name></name-alternatives><email xlink:type="simple">respmgk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Березина</surname><given-names>Г. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Berezina</surname><given-names>G. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миербеков</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Miyerbekov</surname><given-names>Y. M.</given-names></name></name-alternatives><email xlink:type="simple">ergali.m1@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муртазалиева</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Murtazaliyeva</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">respmgk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Республиканское государственное предприятие на праве хозяйственного ведения «Научный центр акушерства, гинекологии и перинатологии» Министерства здравоохранения Республики Казахстан</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Republican State Enterprise on the right of economic management «Scientific Center of Obstetrics, Gynecology and Perinatology» of the Ministry of Health of the Republic of Kazakhstan</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Акционерное общество «Национальный научный центр хирургии им. А.Н. Сызганова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Joint Stock Company «National Scientific Center for Surgery. A.N. Syzganova</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>01</day><month>09</month><year>2018</year></pub-date><volume>17</volume><issue>9</issue><fpage>37</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Святова Г.С., Березина Г.М., Миербеков Е.М., Муртазалиева А.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Святова Г.С., Березина Г.М., Миербеков Е.М., Муртазалиева А.В.</copyright-holder><copyright-holder xml:lang="en">Svyatova G.S., Berezina G.M., Miyerbekov Y.M., Murtazaliyeva A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medgen-journal.ru/jour/article/view/583">https://www.medgen-journal.ru/jour/article/view/583</self-uri><abstract><p>Изучена популяционная частота аллелей и генотипов CYP2C9*2 (rs12254292), *3 (rs9332108), *5 (rs1927465) и *6 (rs12254292); CYP2C19 (rs11187240); VKORC1 (rs9923231), (rs9934438); CYP4F2 (rs2108622); EPHX1 (rs7542242); GGCX (rs12616455); PROC (rs11887389), ассоциированных с эффективностью антикоагулянтной терапии антагонистами витамина К, в казахской популяции. Популяционную выборку составили 2230 условно здоровых казахов. Показано, что в казахской популяции распределение генотипов изученных 11 полиморфизмов находится в соответствии с равновесием Харди-Вайнберга (p&gt;0,05), за исключением CYP2C9 * 3 (р&lt;0,05). Сравнительный анализ показал, что по частотам аллелей CYP2C9*3 , CYP2C9*5 , CYP2C9*6 , неблагоприятных аллелей гена VKORC1 (rs9923231; rs9934438) и GGCX (rs11676382) казахская популяция занимает промежуточное положение между описанными ранее популяциями Европы и Азии. Частота минорных аллелей CYP2C9*2 , CYP2C19 , PROC (rs2069910) в казахской популяции не имела различий с европейскими популяциями, но достоверно отличается от аналогичных показателей популяции Южной Азии.</p></abstract><trans-abstract xml:lang="en"><p>The population frequency of alleles and genotypes CYP2C9*2 (rs12254292), *3 (rs9332108), *5 (rs1927465) и *6 (rs12254292); CYP2C19 (rs11187240); VKORC1 (rs9923231), (rs9934438); CYP4F2 (rs2108622); EPHX1 (rs7542242); GGCX (rs12616455); PROC (rs11887389), associated with the effectiveness of anticoagulant therapy with vitamin K antagonists in the Kazakh population was studied. Population sample was 2230 conditionally healthy Kazakhs. In the Kazakh population, the distribution of genotypes of 11 SNPs is in accordance with the Hardy-Weinberg equilibrium (p&gt;0.05), with the exception of CYP2C9*3 (р&lt;0.05). A comparative analysis showed that the CYP2C9*3, CYP2C9*5, CYP2C9*6, adverse alleles of the gene VKORC1 (rs9923231; rs9934438) and GGCX (rs11676382) alleles frequencies occupy an intermediate position between the previously described populations of Europe and Asia. The frequency of the minor alleles CYP2C9*2, CYP2C19, PROC (rs2069910) in the Kazakh population did not differ from the European populations, but significantly differs from the population of South Asia.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фармакогенетика</kwd><kwd>варфарин</kwd><kwd>цитохромы</kwd><kwd>pharmacogenetics</kwd><kwd>warfarin</kwd><kwd>cytochromes</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">V. G. Manolopoulos, G. Ragia, and A. Tavridou. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics. Aug;12(8):1161-91.</mixed-citation><mixed-citation xml:lang="en">V. G. Manolopoulos, G. Ragia, and A. Tavridou. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics. Aug;12(8):1161-91.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">V. G. Manolopoulos, G. Ragia, and A. Tavridou. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010 Apr; 11(4):493-6.</mixed-citation><mixed-citation xml:lang="en">V. G. Manolopoulos, G. Ragia, and A. Tavridou. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010 Apr; 11(4):493-6.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">http://www.cypalleles.ki.se/cyp2c9.htm.</mixed-citation><mixed-citation xml:lang="en">http://www.cypalleles.ki.se/cyp2c9.htm.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wadelius M, Chen LY, Eriksson N, etc. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007 Mar; 121(1):23-34.</mixed-citation><mixed-citation xml:lang="en">Wadelius M, Chen LY, Eriksson N, etc. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007 Mar; 121(1):23-34.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009 Feb; 10(2):261-6.</mixed-citation><mixed-citation xml:lang="en">Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009 Feb; 10(2):261-6.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">L. Bodin, C. Verstuyft, D. A. Tregouet et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1;106(1):135-40.</mixed-citation><mixed-citation xml:lang="en">L. Bodin, C. Verstuyft, D. A. Tregouet et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1;106(1):135-40.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/ucm123583.pdf.</mixed-citation><mixed-citation xml:lang="en">http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/ucm123583.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y., Shennan M., Reynolds K.K., Johnson N.A., Herrnberger M.R., Valdes R., Jr., Linder M.W. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G&gt;A) and CYP2C9 genotypes. Clin Chem. 2007 Jul;53(7):1199-205.</mixed-citation><mixed-citation xml:lang="en">Zhu Y., Shennan M., Reynolds K.K., Johnson N.A., Herrnberger M.R., Valdes R., Jr., Linder M.W. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G&gt;A) and CYP2C9 genotypes. Clin Chem. 2007 Jul;53(7):1199-205.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">http://warfarindosing.org/Source/Home.aspx</mixed-citation><mixed-citation xml:lang="en">http://warfarindosing.org/Source/Home.aspx</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">H. Schelleman, N. A. Limdi, and S. E. Kimmel. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Br J Clin Pharmacol. 2010 Sep; 70(3): 393-399</mixed-citation><mixed-citation xml:lang="en">H. Schelleman, N. A. Limdi, and S. E. Kimmel. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Br J Clin Pharmacol. 2010 Sep; 70(3): 393-399</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">K. Arvanitidis, G. Ragia, M. Iordanidou et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007 Aug;21(4):419-26.</mixed-citation><mixed-citation xml:lang="en">K. Arvanitidis, G. Ragia, M. Iordanidou et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007 Aug;21(4):419-26.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">R. A. Mirghani, G. Chowdhary, and G. Elghazali. Distribution of the major Cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. Fundam Clin Pharmacol. 2007 Aug;21(4):419-26.</mixed-citation><mixed-citation xml:lang="en">R. A. Mirghani, G. Chowdhary, and G. Elghazali. Distribution of the major Cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. Fundam Clin Pharmacol. 2007 Aug;21(4):419-26.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">L. Yang, W. Ge, F. Yu, and H. Zhu. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement - a systematic review and meta analysis. Thromb Res. 2010 Apr;125(4):e159-66.</mixed-citation><mixed-citation xml:lang="en">L. Yang, W. Ge, F. Yu, and H. Zhu. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement - a systematic review and meta analysis. Thromb Res. 2010 Apr;125(4):e159-66.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">E. Efrati, H. Elkin, E. Sprecher, and N. Krivoy. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Biomed Res Int. 2013; 2013: 315980.</mixed-citation><mixed-citation xml:lang="en">E. Efrati, H. Elkin, E. Sprecher, and N. Krivoy. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Biomed Res Int. 2013; 2013: 315980.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Price, A.L. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006 Aug;38(8):904-9.</mixed-citation><mixed-citation xml:lang="en">Price, A.L. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006 Aug;38(8):904-9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">www.oege.org/software/Hardy-Weinbergequilibriumcalculator</mixed-citation><mixed-citation xml:lang="en">www.oege.org/software/Hardy-Weinbergequilibriumcalculator</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Minoli A Perera, Larisa H Cavallari, Nita A Limdi, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013 Aug 31; 382(9894):790-796.</mixed-citation><mixed-citation xml:lang="en">Minoli A Perera, Larisa H Cavallari, Nita A Limdi, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013 Aug 31; 382(9894):790-796.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">http://www.calculator.net/sample-size-calculator.html?type=1&amp;cl=80&amp;ci=1.52&amp;pp=32&amp;ps=&amp;x=0&amp;y=0</mixed-citation><mixed-citation xml:lang="en">http://www.calculator.net/sample-size-calculator.html?type=1&amp;cl=80&amp;ci=1.52&amp;pp=32&amp;ps=&amp;x=0&amp;y=0</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">http://www.internationalgenome.org/</mixed-citation><mixed-citation xml:lang="en">http://www.internationalgenome.org/</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Iskakova AN, Romanova Voronina AA, Voronina EN, Sikhayeva NS, Belozerceva AB, et al. (2014) Allele Frequency and Genotype Distribution of 9 SNPs in the Kazakh Population. J Pharmacogenomics Pharmacoproteomics 5:129.</mixed-citation><mixed-citation xml:lang="en">Iskakova AN, Romanova Voronina AA, Voronina EN, Sikhayeva NS, Belozerceva AB, et al. (2014) Allele Frequency and Genotype Distribution of 9 SNPs in the Kazakh Population. J Pharmacogenomics Pharmacoproteomics 5:129.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Корчагина РП. Полиморфизм генов биотрансформации ксенобиотиков (CYP2C9, CYP4F2, CYP2D6, GSTM1, GSTT1) и гена VKORC1 в популяциях коренных этносов северной Сибири. Диссертация кандидата биологических наук: 03.02.07. Новосибирск 2012</mixed-citation><mixed-citation xml:lang="en">Корчагина РП. Полиморфизм генов биотрансформации ксенобиотиков (CYP2C9, CYP4F2, CYP2D6, GSTM1, GSTT1) и гена VKORC1 в популяциях коренных этносов северной Сибири. Диссертация кандидата биологических наук: 03.02.07. Новосибирск 2012</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
